Cell line development (CLD) bottlenecks can stall progress on the path to clinical trials. Examine how two novel CLD platforms can accelerate development for efficient protein and vaccine production.
IDT Biologika provides end-to-end services in contract development and manufacturing of vaccines, cell and gene therapeutics, and fill-finish of biologics.
Ajinomoto Bio-Pharma Services is a recognized leader in recombinant protein, plasmid DNA, and critical raw material manufacturing for vaccine and gene therapy applications.
Early manufacturability assessments, complete cGMP solutions, and everything in between. FDB is a leading provider of cell culture services, advancing and delivering life-changing therapies.
Catalent is your one integrated partner with the expertise to get your therapeutic product to market faster, helping you accelerate, simplify, and de-risk your biologics.
Explore process development to GMP manufacturing with a partner with 30 years of experience manufacturing recombinant proteins and flexibility to meet individual customer needs.
Much more than a CMO, AbbVie is an established biopharmaceutical partner providing comprehensive support at every phase of your mAb’s development to commercial life cycle.
CEO and Founder of INCOG BioPharma Services, Cory Lewis, explains how we are proud to be able to manufacture for the future of medicine. Honesty, integrity, transparency, and support.
Ascendia’s team of scientists have decades of combined experience in sterile supplies for clinical trials, making them expert at solving the most difficult formulation challenges.
AGC Biologics is creating innovations and offering the latest technology, helping clients focus on increasing mass, increased speed to market, and overall process intensification.
